What recent performance says about Novavax Novavax (NVAX) has been moving on the radar again, with shares showing a mix of ...

Novavax (NVAX) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day. The stock exceeded ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes.

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

Novavax swings to profit in Q4 CEO remains optimistic despite U.S. regulatory uncertainties Shares surge over 22% after strong results Feb 26 (Reuters) - Novavax (NVAX.O), opens new tab raised its ...

Novavax (NVAX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...

Novavax (NVAX) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to a loss of $0.51 per share a year ago. These ...

GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025. ...